January 25, 2015 5:26 PM ET

Health Care Technology

Company Overview of Schrödinger, LLC

Company Overview

Schrödinger, LLC develops chemical simulation software for use in pharmaceutical and biotechnology research. The company provides products ranging from general molecular modeling programs to a suite of drug design software, including ligand- and structure-based methods. It also provides products in various research areas, including small molecule modeling and simulations, macromolecular modeling and simulations, lead discovery, lead optimization, and visualization and automation. The company’s software allows scientists to accelerate their research and development activities, as well as to make novel discoveries. It serves pharmaceutical and biotech companies, universities, non-profit instit...

101 S.W. Main Street

Suite 1300

Portland, OR 97204

United States

Founded in 1990





Key Executives for Schrödinger, LLC

Vice President and General Counsel
Managing Director and Senior Vice President
Senior Vice President of Strategy and Member of the Scientific Advisory Board
Compensation as of Fiscal Year 2014.

Schrödinger, LLC Key Developments

Schrödinger Inc. and Professor Mark E. Thompson Announce Research Collaboration to Enable Computer-Aided Design of Organic Semiconductor Materials

Schrödinger Inc. and Dr. Mark E. Thompson, Professor of Chemistry at the University of Southern California, announced their joint research collaboration to advance the development and design of organic semiconductor materials through use of atomic-scale simulations. Organic semiconductors are a class of materials that have a wide range of electronic device applications, including organic solar cells and detectors, organic light-emitting diodes (OLEDs), and thin-film transistors. Evaluating expansive chemical space to identify good synthetic targets for organic semiconductors is a challenge that limits the rate of new organic materials development. Schrödinger has previously developed software tools for the discovery of new drug candidates through a method known as virtual screening, which involves the use of high-throughput simulation techniques to predict the candidate systems' chemical properties followed by ranking to identify the most promising lead systems. One of the focuses of this collaboration is to leverage these virtual screening methods for the discovery of novel organic semiconductor materials. Schrödinger's Materials Science Suite 1.0 is available now and provides atomic-scale simulation capabilities for chemical systems used in a wide range of technological applications, including optoelectronics, functional additives, engineered catalysts, and reactive precursors.

BT Group plc and Schrodinger, Inc. Joins to Accelerate the Process of Drug Discovery and Development

BT Group plc and Schrodinger Inc. announced that the two companies are now working together to accelerate the process of drug discovery and development using the BT for Life Sciences cloud platform and Schrodinger's powerful scientific software applications. As part of the joint initiative, Schrodinger becomes a Strategic Member of the BT for Life Sciences partner ecosystem, helping provide research solutions to scientists on a global basis. Schrodinger's software tools will be integrated into BT for Life Sciences as part of BT's R&D Workbench environment. Built on the BT Cloud Compute platform and unveiled at the 10(th) Annual BioIT World meeting last year, BT for Life Sciences is the first cloud service designed to enable collaboration within the life sciences industry for increased productivity in discovery, research and development. One of Schrodinger's key applications, hosted Seurat, will soon be available on the BT Cloud Compute Platform. This application contains tools that help researchers in the discovery and optimization of drug research and provides a means for sharing real-time analysis across the organization. Using the BT platform, Schrodinger can easily integrate data and scientific business processes, enhancing the early discovery process so that ultimately better compounds can be brought to the clinic faster. Because BT for Life Sciences was developed as a secure and segregated platform for scientists, it will enable Schrodinger to work with major pharmaceutical companies and other biotech organizations that need faster and more innovative approaches to drug discovery and development. In the past, researchers would typically provide the IT department with the requirements for each in silico experiment, which could mean a delay in research and discovery as the equipment was purchased and the platform built. Using BT's cloud services for Life Sciences, Schrodinger can now offer their applications quickly and easily with a click-to-launch approach that uses secure, compliant, and scalable cloud computing, storage and databanks, in order to process demanding scientific analysis.

Similar Private Companies By Industry

Company Name Region
Parallax Enterprises, LLC United States
ArioTech Inc. United States
DocsInk LLC United States
ClearPractice LLC United States
Transaction Methods, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Schrödinger, LLC, please visit www.schrodinger.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.